Compare AWI & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AWI | COGT |
|---|---|---|
| Founded | 1860 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Plastic Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 6.2B |
| IPO Year | 1994 | 2018 |
| Metric | AWI | COGT |
|---|---|---|
| Price | $160.74 | $37.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 15 |
| Target Price | ★ $207.50 | $36.21 |
| AVG Volume (30 Days) | 366.6K | ★ 2.6M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.80% | N/A |
| EPS Growth | ★ 17.61 | N/A |
| EPS | ★ 1.55 | N/A |
| Revenue | ★ $1,620,800,000.00 | $7,871,000.00 |
| Revenue This Year | $10.32 | N/A |
| Revenue Next Year | $6.71 | $1,733.58 |
| P/E Ratio | $104.24 | ★ N/A |
| Revenue Growth | ★ 12.11 | N/A |
| 52 Week Low | $150.28 | $8.80 |
| 52 Week High | $206.08 | $43.73 |
| Indicator | AWI | COGT |
|---|---|---|
| Relative Strength Index (RSI) | 54.14 | 64.87 |
| Support Level | $151.13 | $35.39 |
| Resistance Level | $161.85 | $37.69 |
| Average True Range (ATR) | 4.07 | 1.40 |
| MACD | 1.07 | 0.66 |
| Stochastic Oscillator | 74.06 | 71.98 |
Armstrong World Industries Inc designs and manufactures exterior architectural applications, including ceilings, specialty walls, and exterior metal solutions, using materials such as mineral fiber, fiberglass, metal, felt, architectural resin and glass, wood, wood fiber, and glass-reinforced-gypsum. Its segments include Mineral Fiber, which produces suspended mineral fiber and fiberglass ceiling systems and includes results from the Worthington Armstrong Venture (WAVE) for ceiling suspension system (grid) products; Architectural Specialties, which designs, produces, and sources specialty ceilings, walls, and other architectural applications for commercial settings, with revenues mainly project driven; and Unallocated Corporate. The company operates in the United States and Canada.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.